Cogent Biosciences, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Andrew R. Robbins
- Full Time Employees
- 258
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 200 Cambridge Park Drive Waltham MA United States of America 02140
- IPO Date
- Mar 29, 2018
- CIK
- 0001622229
- Website
- cogentbio.com
- Similar Companies
- Business
- Cogent Biosciences, Inc. is a biotechnology company focused on the discovery and development of precision targeted therapies for serious genetically defined diseases. Its main products and services include the development of small molecule drugs and precision medicines, with a leading clinical asset being bezuclastinib, a highly selective and potent tyrosine kinase inhibitor targeting KIT mutations such as KIT D816V and other mutations in KIT exon 17. The company is developing bezuclastinib for the treatment of gastrointestinal stromal tumors (GIST) and systemic mastocytosis, presenting positive Phase 3 trial data including a significant reduction in risk of progression in gastrointestinal cancer patients. Other pipeline programs include investigational therapies targeting mutations in ErbB2, PI3Kα, KRAS, and JAK2, with preclinical candidates such as CGT1263 (a KRAS inhibitor) and CGT1815 (a prodrug designed to optimize pharmacokinetics) advancing toward Investigational New Drug (IND) filings in 2026. Cogent's research also encompasses targeted therapies for cancer types including breast cancer and liver cancer through multiple preclinical compounds. In recent developments, Cogent Biosciences secured a $400 million debt financing facility with SLR Capital Partners to support late-stage clinical development and commercial launch plans for bezuclastinib. The company received Breakthrough Therapy Designation for bezuclastinib and is on track for a New Drug Application (NDA) filing for non-advanced systemic mastocytosis by the end of 2025. It reported positive topline data from multiple pivotal Phase 3 trials including SUMMIT, PEAK, and APEX studies and is engaged in several upcoming scientific presentations highlighting its clinical progress. These include oral presentations at major conferences such as the American Society of Hematology (ASH) in late 2025. Cogent actively communicates its progress through investor and medical community channels and aims to expand its pipeline with innovative solutions targeting genetic drivers of disease. Founded in 2014 and headquartered in Waltham, Massachusetts, with additional operations in Boulder, Colorado, Cogent Biosciences operates globally within the biotechnology and pharmaceutical industry segments. The company primarily serves patients with oncology indications and rare genetic disorders driven by specific mutations. It combines validated biological targets with advanced drug design to create precision therapies that address underlying disease causes, contributing to advancements in genetically defined therapeutic areas. Cogent Biosciences remains a clinical-stage company with a strategic focus on advancing innovative, genetically targeted therapies via partnerships, capital financing, and rigorous clinical development programs to address significant unmet medical needs in the oncology and rare disease markets. Its ongoing programs and financial strategies position it as a notable player in precision medicine development for genetically driven diseases.
Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM)
Cogent Biosciences: A Pre-Commercial Biotech With Commercial-Stage Leverage
Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association (EHA) Congress
Cogent Biosciences Announces Detailed Data from APEX Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis at the 2026 European Hematology Association (EHA) Congress
Cogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
Cogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) with Priority Review for Bezuclastinib in Combination with Sunitinib for Patients with GIST
Cogent Biosciences Announces Participation in the 2026 Jefferies Global Healthcare Conference
Cogent Biosciences Announces Multiple Presentations at the European Hematology Association (EHA) 2026 Congress
Cogent Biosciences Reports Recent Business Highlights and First Quarter 2026 Financial Results
Cogent Biosciences Announces Oral Presentation of Positive Phase 3 PEAK Trial in Gastrointestinal Stromal Tumors (GIST) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
Cogent Biosciences Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026
Cogent Biosciences: Blockbuster Potential, Premium Valuation, Still A 'Buy'
Head to Head Contrast: Cogent Biosciences (NASDAQ:COGT) versus GT Biopharma (NASDAQ:GTBP)
Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors (GIST)
Cogent Biosciences, Cigna Group among top healthcare stocks, according to UBS analysts
This $116 Million Buy Joins a 360% Stock Run and Seemingly Signals Conviction in a Key Drug Launch
High-Flying Biotech Stock Up 360% Faces $48 Million Trim but Remains This Fund's Largest Holding
Biotech Stock Up 372% Gets Sold as New Pick Rises 40% in 2026
COGT Rise as FDA Accepts Bezuclastinib NDA in Non-Advanced SM